Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Posts
- Category: important (continued)
- Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology
- Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia
- Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease
- Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease
- Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
- The Abstracts for the 2013 World Congress Huntington’s Disease 15-18 Sept, Rio de Janeiro, Brazil
- The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3
- The Lancet Neurology publishes Prana’s Huntington’s Disease Trial
- TSRI Scientists Find Drug That Helps Huntington's Disease-Afflicted Mice-and Their Offspring
- Turning skin cells into brain cells: a Huntington's disease research breakthrough?
- UB researchers discovered new applications of the drug fingolimod to improve cognitive deficits in Huntington's disease
- UBC scientists develop test to measure effectiveness of treatments for Huntington’s disease
- UCI team finds method to reduce accumulation of damaging Huntington’s disease protein
- UCI team gets $5 million to create stem cell treatment for Huntington’s disease
- UCI-led study demonstrates how Huntington’s disease proteins spread from cell to cell
- UCLA researchers identify molecular ‘switch’ that causes Huntington’s disease–like symptoms in mice
- UF Health researchers identify novel proteins linked to Huntington’s disease
- Uguale, ma diversa: la Malattia di Huntington Giovanile -
- Uguale, ma molto diversa: la Malattia di Huntington Giovanile
- uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease
- uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
- uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- University of Toronto Researcher First to Open Lab Notes in Real Time
- Unlocking a Mystery of Human Disease . . . in Space
- Update confirms Huntington's disease 'gene silencing' trial on track
- UW Receives Patent for Huntington’s Disease Treatment
- UW Scientists Find Excess Mitochondrial Iron, Huntington’s Disease Link
- Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)
- WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
- Would ewe believe it? GM1, sheep and Huntington's disease
- Category: IONIS-HTTRx
- 9th June, 2016 - Professor Sarah Tabrizi, Director of UCL’s Huntington’s Disease Centre, gives keynote speech at Google’s Zeitgeist event
- Discovery and Early Clinical Development of ISIS-HTTRx, the First HTT-Lowering Drug to Be Tested in Patients with Huntington’s Disease
- Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
- EuroBuzz 2014: day two
- First Huntington's patients dosed with 'gene silencing' drug
- First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
- How NOT to write a news article about a clinical trial
- Huntington's Disease Therapeutics Conference 2016 - day 2
- Ionis Phase I Huntington’s disease trial at halfway mark: ‘No surprises so far’ means good news
- IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
- Liftoff: First humans treated with gene silencing drugs for HD!
- New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
- Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
- PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
- Roche announces details of its 'pivotal' huntingtin-lowering study
- Roche gears up for pivotal Phase 3 Huntington’s disease gene-silencing clinical trial
- Roche: less frequent dosing for Phase 3 Huntington’s clinical trial, easing burden on patients
- The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3
Plugin by dagondesign.com
